14:46 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Arsanis discontinues Phase II of lead anti-infective

Arsanis Inc. (NASDAQ:ASNS) discontinued a double-blind, international Phase II trial of lead candidate ASN100 to prevent...
16:49 , Jun 28, 2018 |  BC Extra  |  Clinical News

Arsanis discontinues Phase II of lead anti-infective, shares plummet

Arsanis Inc. (NASDAQ:ASNS) discontinued a Phase II trial of lead candidate ASN100 to prevent...
19:45 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Arsanis raises $60M IPO and private placement

On Nov. 15, Arsanis Inc. (NASDAQ:ASNS) raised $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through the sale of 4 million shares in the IPO underwritten...
18:31 , Nov 16, 2017 |  BC Extra  |  Financial News

Arsanis rises on $60M IPO and private placement

Arsanis Inc. (NASDAQ:ASNS) jumped $4.03 (40%) to $14.03 on its first day of trading Thursday after raising $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through...
19:55 , Apr 26, 2017 |  BC Extra  |  Financial News

Gates Foundation leads Arsanis' $45.5M series D

Infectious disease company Arsanis Inc. (Waltham, Mass.) raised $45.5 million in a series D round led by the Bill & Melinda Gates Foundation (Seattle. Wash.), a new investor. Also participating were new investors GV and...
21:21 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

ASN100: Ph II started

Arsanis began a double-blind, placebo-controlled, international Phase II trial to evaluate a single dose of IV ASN100 in about 350 high-risk, mechanically ventilated patients. ASN100 was discovered under a deal with Adimab, which is using...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

ASN100: Phase I started

Arsanis began an Austrian Phase I trial of ASN100 in healthy volunteers. ASN100 was discovered under a deal with Adimab, which is using its technology to discover and optimize mAbs against targets designated by Arsanis...
00:39 , Sep 4, 2013 |  BC Extra  |  Financial News

Arsanis raises $20M series B round

Arsanis Inc. (Vienna, Austria) raised $20 million in a series B round led by new investor NeoMed Management. Existing investors OrbiMed Advisors; Polaris Venture Partners; and SV Life Sciences also participated. NeoMed's Claudio Nessi joined...